Investors
REPLICor is a private Canadian company based in Montreal. Most of our shareholders are private individuals and companies that share our vision of creating a drug that has the potential to revolutionize the treatment of patients with chronic hepatitis. This drug is now in the human trial phase. In addition, this same drug has been shown in vitro and in vivo to be effective against a wide spectrum of other important viral infections.
REPLICor was nominated as one of Canada’s Top 10 Life Sciences Companies for the years 2004/2005 and for 2007/2008 by the Ottawa Centre for Research and Innovation.
See: http://www.topcanadiancompanies.ca/winners/alumni.pdf
Periodically REPLICor seeks new investment funds. If you have an interest in becoming a shareholder please contact the Company for additional information.
Michel Bazinet, MD
Chairman of the Board and CEO
Tel.: (514) 496-9016